If bile acid deficiency is contributing to your SIBO, standard breath testing will tell you that you have bacterial overgrowth but not why. Identifying the bile component requires separate testing, and here is where SIBO patients in different countries face very different options. The gold standard test for bile acid malabsorption, the SeHCAT scan, is widely available in Europe and the UK but has never been approved in the United States. American patients must rely on blood markers, therapeutic trials, and indirect evidence from fat-soluble vitamin levels to build a case for bile-related SIBO. This article covers the available diagnostic tools, their strengths and limitations, and how bile acid assessment fits into a comprehensive SIBO root cause evaluation.
SeHCAT scanning: the gold standard
The selenium-75-homocholic acid taurine (SeHCAT) test is a nuclear medicine scan that directly measures bile acid retention. The patient swallows a capsule containing a radiolabeled synthetic bile acid (SeHCAT), and a gamma camera measures abdominal radioactivity on day 1 and again on day 7. The percentage of the original dose retained at day 7 indicates how efficiently the enterohepatic circulation is reclaiming bile acids. Normal retention is greater than 15%. Mild bile acid malabsorption is defined as 10-15% retention, moderate as 5-10%, and severe as less than 5%.
SeHCAT has sensitivity of 80-94% and specificity of 70-100% for bile acid malabsorption, depending on the cutoff used. It is the standard diagnostic test in the United Kingdom, Scandinavia, and several other European countries. In the US, the radiolabeled compound has never received FDA approval, making the test effectively unavailable. This is a significant diagnostic gap, as bile acid malabsorption is estimated to affect 1-2% of the general population and a much higher percentage of patients with chronic diarrhea.
7-alpha-C4 blood test
Serum 7-alpha-hydroxy-4-cholesten-3-one (commonly abbreviated as 7-alpha-C4 or C4) is an intermediate in the bile acid synthesis pathway. When bile acid loss increases (as in malabsorption), the liver compensates by upregulating bile acid production, and serum 7-alpha-C4 levels rise accordingly. Measuring this blood marker provides an indirect assessment of bile acid synthesis rate and, by extension, bile acid loss. The test requires a fasting morning blood draw (bile acid synthesis has a diurnal pattern, with peak levels in the afternoon).
Studies have shown good correlation between 7-alpha-C4 levels and SeHCAT results, with a sensitivity of approximately 70-90% depending on the threshold used. The test is available through specialty labs in the US, including Quest Diagnostics and some academic medical center laboratories. An elevated 7-alpha-C4 level in a patient with diarrhea-predominant symptoms supports a diagnosis of bile acid malabsorption. The main limitation is that results can be affected by cholesterol-lowering medications (statins) and by timing of the blood draw.
Cholestyramine therapeutic trial
In the absence of SeHCAT availability, many clinicians use a cholestyramine therapeutic trial as a practical diagnostic tool. Cholestyramine is a bile acid sequestrant that binds bile acids in the intestinal lumen, preventing them from stimulating colonic fluid secretion (which is the mechanism of bile acid diarrhea). The patient takes cholestyramine (typically 4 grams before meals, one to three times daily) for 2-4 weeks. If diarrhea improves significantly, this supports a diagnosis of bile acid diarrhea with a positive predictive value of approximately 80%.
âšī¸Important caveat for SIBO patients: cholestyramine binds bile acids, which further reduces the antimicrobial bile acid concentration in the small intestine. While it may improve diarrhea, it could theoretically worsen SIBO by reducing one of the defenses against bacterial overgrowth. If you are using a cholestyramine trial, monitor for worsening bloating or gas that might indicate increased bacterial fermentation.
Fat-soluble vitamin testing
Testing fat-soluble vitamin levels provides indirect evidence of bile acid insufficiency. Because vitamins A, D, E, and K require bile acid micelles for absorption in the small intestine, deficiencies in these vitamins suggest inadequate bile acid function, whether from primary insufficiency or SIBO-mediated bile salt deconjugation. The tests are widely available and routinely ordered.
- Vitamin D (25-hydroxyvitamin D): The most commonly tested. Levels below 30 ng/mL are insufficient, below 20 ng/mL are deficient. Persistently low levels despite oral supplementation suggest malabsorption.
- Vitamin A (retinol): Deficiency causes night blindness and dry eyes. Tested less routinely but important in suspected bile acid insufficiency.
- Vitamin E (alpha-tocopherol): Deficiency can cause peripheral neuropathy, ataxia, and muscle weakness. Important to test in patients with neurological symptoms.
- Vitamin K: Not typically measured directly. Instead, prothrombin time (PT) and INR provide functional assessment. Prolonged PT/elevated INR suggests vitamin K deficiency.
- Comprehensive metabolic testing should also include iron, B12, and folate, as SIBO can cause malabsorption of these nutrients through separate mechanisms.
UDCA supplementation
Ursodeoxycholic acid (UDCA, brand name Actigall or Urso) is a naturally occurring bile acid that constitutes about 3% of the human bile acid pool. When administered as a supplement (typically 250-500 mg twice daily), it improves bile flow (choleresis), replaces toxic hydrophobic bile acids with less toxic hydrophilic UDCA, has anti-inflammatory properties, and may improve bile acid pool composition. UDCA is FDA-approved for dissolving gallstones and for primary biliary cholangitis but is used off-label for various biliary conditions.
For SIBO patients with bile acid issues, UDCA may offer several benefits. By improving bile flow, it can increase the delivery of bile acids to the small intestine. Its anti-inflammatory properties may benefit patients with bile duct inflammation or hepatobiliary dysfunction. However, UDCA is a prescription medication with potential interactions and side effects, and its use for SIBO-related bile acid issues is off-label. A gastroenterologist or hepatologist should guide this decision based on individual clinical circumstances.
Putting it together: a practical approach
For SIBO patients who suspect bile acid involvement, a practical diagnostic approach combines several of these tools. Start with fat-soluble vitamin levels (widely available, low cost) and a stool assessment for steatorrhea. If vitamin deficiencies or steatorrhea are present, pursue 7-alpha-C4 blood testing (if available in your area) or discuss a cholestyramine therapeutic trial with your gastroenterologist. If you are in the UK or Europe, request SeHCAT scanning directly. Combine these results with your breath test findings and surgical history to build a comprehensive picture of whether bile acid deficiency is contributing to your SIBO.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.